The first participant has been enrolled in a two-part Phase 3 clinical trial testing IKT-001, Inhibikase Therapeutics’ experimental formulation of imatinib, in people with pulmonary arterial hypertension (PAH). The Phase 3 IMPROVE-PAH trial (NCT07365332) is expected to enroll nearly 500 adults with various forms of PAH, ages 18…